glp-1 receptor agonists in idiopathic intracranial hypertension Efficacy of glucagon-like peptide-1 hypertension: A systematic review and meta-analysis The effect of GLP-1 agonist
Description
doi: 10.1016/S0140-6736(15)00803-X 193 NewsomePNBuchholtzKCusiKLinderMOkanoueTRatziuVet al
The REWIND trial mainly assessed the cardiovascular outcomes of dulaglutide over up to 8 years
GLP-1R agonists now appear to be efficacious in reducing heart disease risk and in treating certain chronic kidney diseases, expanding their likely future use
Risk of thyroid tumors with GLP-1 receptor agonists: a retrospective cohort study
doi: 10.1111/dom.14725 23 MollHFreyEGerberPGeidlBKaufmannMBraunJet al
[DOI] [PubMed] [Google Scholar] 106.Escobar Cervantes C
